Resveratrol - Sirtris
Alternative Names: 184072; GSK184072; SRT 501Latest Information Update: 05 Nov 2023
At a glance
- Originator Sirtris Pharmaceuticals
- Developer GlaxoSmithKline; Sirtris
- Class Antidementias; Antineoplastics; Antithrombotics; Cardiovascular therapies; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
- Mechanism of Action Antioxidants; Ribonucleotide reductase inhibitors; SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer metastases; Colorectal cancer; MELAS syndrome; Multiple myeloma; Multiple sclerosis; Optic neuritis; Type 2 diabetes mellitus
Most Recent Events
- 02 Dec 2010 Discontinued - Phase-II for Multiple myeloma in Denmark (PO)
- 02 Dec 2010 Discontinued - Phase-II for Multiple myeloma in United Kingdom (PO)
- 22 Apr 2010 Suspended - Phase-II for Multiple myeloma in combination with bortezomib in Denmark (PO)